<DOC>
	<DOCNO>NCT02668653</DOCNO>
	<brief_summary>This phase 3 , randomize , double-blind , placebo-control global study . The purpose study compare effect quizartinib versus placebo ( administered standard induction consolidation chemotherapy , administer maintenance therapy 12 cycle ) event-free survival subject FLT3-ITD positive AML .</brief_summary>
	<brief_title>Quizartinib With Standard Care Chemotherapy Maintenance Therapy Patients With Newly Diagnosed FLT3-ITD ( + ) AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Must competent able comprehend , sign , date Ethics Committee ( EC ) Institutional Review Board approve Informed Consent Form ( ICF ) performance studyspecific procedure test ; 2 . ≥18 year minimum legal adult age ( whichever great ) ≤75 year ( Screening ) ; 3 . Newly diagnose , morphologically document primary AML AML secondary myelodysplastic syndrome , base World Health Organization ( WHO ) 2008 classification ( Screening ) ; 4 . Eastern Cooperative Oncology Group performance status 02 ( Screening ) ; 5 . Presence FLT3ITD activate mutation bone marrow ( allelic ratio ≥3 % FLT3ITD/total FLT3 ) ; 6 . Subject receive standard `` 7+3 '' induction chemotherapy regimen specify protocol ; 7 . Adequate renal function define : Serum creatinine ≤1.5 × upper limit normal ( ULN ) ; Glomerular filtration rate &gt; 50 mL/min/1.73m2 , calculate modify Cockcroft Gault equation ; 8 . Adequate hepatic function define : Total serum bilirubin ≤1.5 × ULN ; Serum alkaline phosphatase , aspartate transaminase alanine transaminase ≤2.5 × ULN ; 9 . Serum electrolyte ( potassium , calcium , magnesium ) within normal limit . If outside normal limit , subject eligible electrolyte correct ; 10 . If female , must either postmenopausal ( menstrual period minimum 12 month ) , surgically sterile , childbearing potential , must negative serum pregnancy test upon entry study must willing use maximally effective doublebarrier birth control period therapy contraception 3 month follow last investigational drug dose ; 11 . If male , must surgically sterile willing use effective doublebarrier contraception method upon enrollment , course study , 3 month follow last investigational drug dose . 1 . Diagnosis acute promyelocytic leukemia ( APL ) , FrenchAmericanBritish classification M3 WHO classification APL translocation , ( 15 ; 17 ) ( q22 ; q12 ) , BCRABL positive leukemia ( ie , chronic myelogenous leukemia blast crisis ) ; 2 . Diagnosis AML secondary prior chemotherapy radiotherapy neoplasm ; 3 . Prior treatment AML , except follow allowance : Leukapheresis ; Treatment hyperleukocytosis hydroxyurea ; Cranial radiotherapy central nervous system ( CNS ) leukostasis ; Prophylactic intrathecal chemotherapy ; Growth factor/cytokine support ; 4 . Prior treatment quizartinib FLT3ITD inhibitor ; 5 . Prior treatment investigational drug device within 30 day prior Randomization currently participate investigational procedure ; 6 . History known CNS leukemia , include cerebrospinal fluid positive AML blast ; lumbar puncture recommend subject symptom CNS leukemia rule extramedullary CNS involvement ; 7 . History malignancy , except adequately treat nonmelanoma skin cancer , curatively treat insitu disease , solid tumor curatively treat evidence disease least 2 year ; 8 . Uncontrolled significant cardiovascular disease , include follow : Bradycardia le 50 beat per minute , unless subject pacemaker ; QTcF interval &gt; 450 msec ; Diagnosis suspicion long QT syndrome ( include family history long QT syndrome ) ; Systolic blood pressure ≥180 mmHg diastolic blood pressure ≥110 mmHg ; History clinically relevant ventricular arrhythmia ( eg , ventricular tachycardia , ventricular fibrillation , Torsade de Pointes ) ; History second ( Mobitz II ) third degree heart block ( subject pacemaker eligible history faint clinically relevant arrhythmia use pacemaker ) ; History uncontrolled angina pectoris myocardial infarction within 6 month prior Screening ; History New York Heart Association Class 3 4 heart failure ; Known history leave ventricular ejection fraction ( LVEF ) ≤45 % le institutional low limit normal ; History complete leave complete right bundle branch block ; 9 . Active acute chronic systemic fungal , bacterial , viral infection well controlled antifungal , antibacterial antiviral therapy ; 10 . Known active clinically relevant liver disease ( eg , active hepatitis B , active hepatitis C ) 11 . Known history human immunodeficiency virus ( HIV ) . Subjects test HIV prior randomization require local regulation EC ; 12 . History hypersensitivity excipients quizartinib/placebo tablet ; 13 . Females pregnant breastfeeding ; 14 . Otherwise consider inappropriate study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Newly diagnose Acute Myeloid Leukemia</keyword>
	<keyword>FLT3-ITD positive</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Consolidation chemotherapy</keyword>
	<keyword>Maintenance chemotherapy</keyword>
	<keyword>Quizartinib</keyword>
	<keyword>Receptor tyrosine kinase inhibitor</keyword>
	<keyword>FMS-like tyrosine kinase 3</keyword>
	<keyword>AC220</keyword>
	<keyword>FLT3-ITD</keyword>
	<keyword>AML</keyword>
</DOC>